Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity

Journal of Virology

Volumn 71, Issue 7, 1997, Pages 5069-5079

  Cole, Kelly Stefano ^a   Rowles, Jennifer L ^a   Jagerski, Beth A ^a   Murphey Corb, Michael ^b   Unangst, Tami ^c   Clements, Janice E ^c   Robinson, James ^d   Wyand, Michael S ^e   Desrosiers, Ronald C ^f   Montelaro, Ronald C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TSI Mason Laboratories   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; HOST RESISTANCE; IMMUNIZATION; IMMUNOREACTIVITY; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0030974498     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.7.5069-5079.1997     Document Type: Article

References (50)

1. Anderson, M. G., D. Hauer, D. P. Sharma, S. V. Joag, O. Narayan, M. C. Zink, and J. E. Clements. 1993. Analysis of envelope changes acquired by SIVmac239 during neuroadaptation in rhesus macaques. Virology 195:616-626.
2. Andersson, A., V. Vetter, L. Kreutzer, and G. Bauer. 1994. Avidities of IgG directed against viral capsid antigen or early antigen: useful markers for significant Epstein-Barr virus serology. J. Med. Virol. 43:238-244.
3. Barker, E., S. W. Barnett, L. Stamatatos, and J. A. Levy. 1995. The human immunodeficiency viruses, p. 1-96. In J. A. Levy (ed.), The Retroviridae. Plenum Press, New York, N.Y.
4. Baskin, G. B., L. N. Martin, S. R. S. Rangan, B. J. Gormus, M. Murphey-Corb, R. H. Wolf, and K. F. Soike. 1986. Transmissible lymphoma and simian acquired immunodeficiency syndrome in rhesus macaques. JNCI 77:127-139.
5. Blackburn, N. K., T. G. Besselaar, B. D. Schoub, and K. F. O'Connell. 1991. Differentiation of primary cytomegalovirus infection from reactivation using the urea denaturation test for measuring antibody avidity. J. Med. Virol. 33:6-9.
6. Boppana, S. B., and W. J. Britt. 1995. Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J. Infect. Dis. 171:1115-1121.
7. Brostrom, C., A. Sonnerberg, and M. Sallberg. 1995. Human immunodeficiency virus type-1 infected patients with no disease progression display high avidity antibody to autologous V3 sequences. J. Infect. Dis. 171:509-511.
8. + patients with haemophilia: titre and avidity. Clin. Exp. Immunol. 93:331-336.
9. Chargelegue, D., C. M. Stanley, C. M. O'Toole, B. T. Colvin, and M. W. Steward. 1995. The absence or loss of antibodies of high affinity to human immunodeficiency virus (HIV) is associated with disease progression in HIV-1 infected patients. J. Infect. Dis. 172:897.
10. Clements, J. E., R. C. Montelaro, M. C. Zink, A. M. Amadee, S. Miller, A. M. Trichel, B. Jagerski, D. Hauer, L. N. Martin, R. P. Bohm, and M. Murphey-Corb. 1995. Cross-protective immune responses induced in rhesus macaques by immunization with an attenuated macrophage-tropic simian immunodeficiency virus. J. Virol. 69:2737-2744.
11. Daniel, M. D., F. Kirchhoff, S. C. Czajak, P. K. Sehgal, and R. C. Desrosiers. 1992. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258:1938-1941.
12. Desrosiers, R. C. 1990. The simian immunodeficiency viruses. Annu. Rev. Immunol. 8:557-578.
13. Devash, Y., T. Calvelli, D. Wood, K. Reagan, and A. Rubinstein. 1990. Vertical transmission of HIV-1 is correlated with the absence of high affinity/ avidity maternal antibodies to the gp120 principal neutralizing domain. Proc. Natl. Acad. Sci. USA 87:3445-3449.
14. Gray, J. J. 1995. Avidity of EBV VCA-specific IgG antibodies: distinction between recent primary infection, past infection and reactivation. J. Virol. Methods 52:95-104.
15. Hammond, S. A., S. J. Cook, D. L. Lichtenstein, C. J. Issel, and R. C. Montelaro. 1997. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J. Virol. 71:3840-3852.
16. Hedman, K., J. Hietala, A. Tiilikainen, A.-L. Hartikainen-Sorri, K. Raiha, J. Suni, P. Vaananen, and M. Pietilainen. 1989. Maturation of immunoglobulin G avidity after rubella vaccination studied by an enzyme linked immunosorbent assay (avidity-ELISA) and by haemolysis typing. J. Med. Virol. 27:293-298.
17. Hedman, K., and I. Seppala. 1988. Recent rubella virus infection indicated by a low avidity of specific IgG. J. Clin. Immunol. 8:214-221.
18. Javaherian, K., A. J. Langlois, S. Schmidt, N. Kaufmann, N. Cates, J. P. M. Langedijk, R. H. Meloen, R. C. Desrosiers, D. P. W. Burns, D. P. Bolognesi, and S. D. Putney. 1994. The principal neutralizing determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 256:320.
19. Junker, A. K., and P. Tilley. 1994. Varicella-zoster virus antibody avidity and IgG-subclass patterns in children with recurrent chickenpox. J. Med. Virol. 43:119-124.
20. Kangro, H. O., S. Manzoor, and D. R. Harper. 1991. Antibody avidity following varicella-zoster virus infections. J. Med. Virol. 33:100-105.
21. Karber, G. 1931. Beitrag zue kollektiven Behandlung pharmakologischer Reinhenversuche. Arch. Exp. Pathol. Pharmakol. 162:480-487.
22. Langlois, A. J., K. J. Weinhold, T. J. Matthews, M. L. Greenberg, and D. P. Bolognesi. 1992. The ability of certain SIV vaccines to provoke reactions against normal cells. Science 255:292-293.
23. Lewis, M. G., W. R. Elkins, F. E. McCutchan, R. E. Benveniste, C. Y. Lai, D. C. Montefiori, D. S. Burke, G. A. Eddy, and A. Shafferman. 1993. Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection. Vaccine 11:1347-1355.
24. Lohman, B. L., M. B. McChesney, C. J. Miller, E. McGowan, S. M. Joye, K. A. Van Rompay, E. Reay, L. Antipa, N. C. Pedersen, and M. L. Marthas. 1994. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J. Virol. 68:7021-7029.
25. Lu, S., J. Arthos, D. C. Montefiori, Y. Tasutomi, K. Manson, F. Mustafa, E. Johnson, J. C. Santoro, J. Wissink, J. I. Mullins, J. R. Haynes, N. L. Letvin, M. S. Wyand, and H. L. Robinson. 1996. Simian immunodeficiency virus DNA vaccine trial in macaques. J. Virol. 70:3978-3991.
26. Means, G. E., and R. E. Feeney. 1971. Chemical modifications of proteins, p. 216-222. Holden-Day, Inc., San Francisco, Calif.
27. Meurman, O., M. Waris, and K. Hedman. 1992. Immunoglobulin G antibody avidity in patients with respiratory syncytial virus infection. J. Clin. Microbiol. 30:1479-1484.
28. Montefiori, D. C., K. A. Reimann, N. L. Letvin, J. Zhou, and S.-L. Hu. 1995. Studies of complement-activating antibodies in the SIV/macaque model of acute primary infection and vaccine protection. AIDS Res. Hum. Retroviruses 11:963-970.
29. Montelaro, R. C., and D. P. Bolognesi. 1995. Vaccines against retroviruses, p. 605-656. In J. A. Levy (ed.), The Retroviridae. Plenum Press, New York, N.Y.
30. Montelaro, R. C., C. Grund, M. Raabe, B. Woodson, R. F. Cook, S. Cook, and C. J. Issel. 1996. Characterization of protective and enhancing immune responses to equine infectious anemia virus resulting from experimental vaccines. AIDS Res. Hum. Retroviruses 12:413-415.
31. Morgan-Capner, P., and H. I. J. Thomas. 1988. Serological distinction between primary rubella infection and reinfection. Lancet i:1397.
32. 31a. Murphy-Corb, M., and R. Desrosiers. Unpublished data.
33. Murphey-Corb, M., L. N. Martin, B. Davison-Fairburn, R. C. Montelaro, M. Miller, M. West, S. Ohkawa, G. B. Baskin, J.-Y. Zhang, S. D. Putney, A. C. Allison, and D. A. Eppstein. 1989. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science 246:1293-1297.
34. Murphey-Corb, M., R. C. Montelaro, M. A. Miller, M. West, L. N. Martin, B. Davison-Fairburn, S. Ohkawa, G. B. Baskin, J.-Y. Zhang, G. B. Miller, S. D. Putney, A. C. Allison, and D. A. Eppstein. 1991. Efficacy of SIV/ DeltaB670 glycoprotein-enriched and glycoprotein-depleted subunit vaccines in protecting against infection and disease in rhesus monkeys. AIDS 5:655-662.
35. Ohkawa, S., K. Xu, L. A. Wilson, R. C. Montelaro, L. N. Martin, and M. Murphey-Corb. 1995. Analysis of envelope glycoprotein-specific antibodies from SIV-infected and gp110-immunized monkeys in ACC and ADCC assays. AIDS Res. Hum. Retroviruses 11:395-403.
36. Polanec, J., I. Seppala, S. Rousseau, and K. Hedman. 1994. Evaluation of protein-denaturing immunoassays for avidity of immunoglobulin G to rubella virus. J. Clin. Lab. Anal. 8:16-21.
37. Regier, D. A., and R. C. Desrosiers. 1990. The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus. AIDS Res. Hum. Retroviruses 6:1221-1231.
38. Robinson, J. E., D. Holton, J. Liu, H. McMurdo, A. Murciano, and R. Gohd. 1990. A novel enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to HIV-1 envelope glycoproteins based on immobilization of viral glycoproteins in microtiter wells coated with concanavalin A. J. Immunol. Methods 132:63-71.
39. Robinson, J. E., D. Holton, S. Pacheo-Morell, J. Liu, and H. McMurdo. 1990. Identification of conserved and variant epitopes of human immunodeficiency virus type 1 (HIV-1) gp120 by human monoclonal antibodies produced by EBV-transformed cell lines. AIDS Res. Hum. Retroviruses 6:567-579.
40. Salmi, A. A. 1991. Antibody affinity and protection in virus infections. Curr. Opin. Immunol. 3:503-506.
41. Sharma, D. P., M. C. Zink, M. Anderson, R. Adams, J. E. Clements, S. V. Joag, and P. Narayan. 1992. Derivation of neurotropic simian immunodeficiency virus from exclusively lymphocytetropic parental virus: pathogenesis of infection in macaques. J. Virol. 66:3550-3556.
42. Simon, F., C. Rahimy, A. Krivine, M. Levine, J. M. Pepin, D. Lapierre, E. Denamur, L. Vernoux, A. DeCrepy, P. Blot, E. Vilmer, and F. Brun-Vezinet. 1993. Antibody avidity measurement and immune complex dissociation for serological diagnosis of vertically acquired HIV-1 infection. J. Acquired Immune Defic. Syndr. 6:201-207.
43. Stott, E. J. 1991. Anti-cell antibody in macaques. Nature 353:393.
44. Thomas, H. I. J., and P. Morgan-Capner. 1991. Rubella-specific IgG1 avidity: a comparison of methods. J. Virol. Methods 31:219-228.
45. Thomas, H. I. J., S. Wilson, C. M. O'Toole, C. M. Lister, A. M. Saees, R. P. F. Watkins, and P. Morgan-Capner. 1996. Differential maturation of avidity of IgG antibodies to gp41, p24 and p17 following infection with HIV-1. Clin. Exp. Immunol. 103:185-191.
46. Ward, K. N., W. Dhaliwal, K. L. Ashworth, E. J. Clutterbuck, and C. G. Teo. 1994. Measurement of antibody avidity for hepatitis C virus distinguishes primary antibody responses from passively acquired antibody. J. Med. Virol. 43:367-372.
47. Ward, K. N., J. J. Gray, M. E. Joslin, and M. J. Sheldon. 1993. Avidity of IgG antibodies to human herpesvirus-6 distinguishes primary from recurrent infection in organ transplant recipients and excludes cross-reactivity with other herpesviruses. J. Med. Virol. 39:44-49.
48. Wregitt, T. G., J. J. Gray, S. Aloyisus, M. Contreras, and J. A. Barbara. 1990. Antibody avidity test for recent infection with hepatitis C virus. Lancet 335:789.
49. Wyand, M. S., K. H. Manson, M. Garcia-Moll, D. Montefiori, and R. C. Desrosiers. 1996. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J. Virol. 70:3724-3733.
50. Zinkernagel, R. M. 1996. Immunology taught by viruses. Science 271:173-178.